Latest Conference Articles

The CAPSTONE-1 trial demonstrated a new antiviral aimed to reduce flu symptoms with possible NDA submission.

The UN and WHO aim to reduce the burden of cholera globally by 90% reduction in deaths by 2030.

Since 2000 there's been a 30% overall reduction in malaria, however, a vaccine is needed as another tool.

Catch up on what you missed in how HIV affects the brain.

Learn more about the decrease in yellow fever vaccine production that will last until mid-2018.

Treated in hospital settings, cUTI has been traditionally treated with quinolones due to a patient’s ability to transfer from IV to oral form when they’re discharged.

Why is delafloxacin unique compared to other fluoroquinolones? Find out more.

What expecting mothers with Zika virus should know.

The D/C/F/TAF combination tablet showed 2.5% virologic rebound and 94.9% virologic suppression in almost 800 patients.

As drug costs continue to rise, many are hoping generics will bring relief. But will they?

Antibiotics are not harmless drugs, but recent findings suggest that dentists may be prescribing them under that assumption.

Rochelle Walensky, MD, MPH, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, discusses the current and future state of costs for HIV medications.

Rochelle Walensky, MD, MPH, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, discusses the future for HIV drug prices.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about challenges of Hepatitis C treatment.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about the current state and future of Hepatitis C.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about the challenges treating co-infected HIV and HCV patients.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about the hottest topic in infectious disease.

The drug is in phase 3 trials for CABP, and shows potential for pneumonia associated with S. aureas.

Patients with HIV are living longer. How does their condition affect the cognitive decline that comes with aging?

Rochelle Walensky, MD, MPH, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, discusses the impact and potential for antivirals in the US.

Real world results garnered positive outcomes in the historically difficult-to-treat population.

Physicians looking to provide effective treatment to co-infected patients mustn't overlook uncontrolled viremia or substance abuse, according to a new study.

The CDC and local agencies have partnered to combat the outbreak, but it’s not under control yet.

Tom Chiller, MD, MPH, Mycotic Diseases Branch, Centers for Disease Control and Prevention, talks about treatment options for Candida auris and multi-drug resistant treatment options.

Tom Chiller, MD, MPH, Mycotic Diseases Branch, Centers for Disease Control and Prevention, discusses Candida auris.

Paul Ananth Tambyah, MD, Dept. of Medicine, Infectious Disease, National University of Singapore, provides an overview of infection control approach for travelers with either epidemic or endemic diseases from various parts of the world.

Individuals engaged in riskier behaviors and relationships appear to be more inclined to continue taking treatment.

Treating opioid use disorder can reduce mortality and curb spreading infections in people who use drugs.

The sc2Wear Infusor allows the opportunity to deliver furosemide subcutaneously and at home, to keep HF patients in need of diuresis out of the hospital.

New technologies are creating opportunities for physicians to provide better treatment and differentiate themselves in a crowded health care space.